ongoing

PACIFIC-Stroke is a randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke.

Primary outcome measures:

  • Number of participants with symptomatic ischemic stroke or covert brain infarcts detected by Magnetic resonance imaging (MRI). Baseline up to 6 months.
  • Time from randomization to first occurrence of International Society on Thrombosis and Hemostasis (ISTH) major bleeding and clinically relevant non-major (CRNM) bleeding . Baseline up to 12 months.
Study Type

Interventional - Drug

Study Design

Randomized placebo controlled double-blind parallel group phase 2

NO. of Countries

25

NO. of Sites

250

NO. of Participants

1800

Study Period

2020 - 2022

Sponsor

Bayer

Back To Top